Advaxis, Inc. Engages the Numoda Corporation to Oversee Phase II Clinical Trials of ADXS11-001
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and cervical intraepithelial neoplasia (CIN; cervical dysplasia).